TC Biopharm (NASDAQ:TCBPW) Trading Up 35.8%
TC Biopharm (NASDAQ:TCBPW) Trading Up 35.8%
TC Biopharm (Holdings) Plc (NASDAQ:TCBPW – Get Rating) shares were up 35.8% during trading on Monday . The company traded as high as $0.12 and last traded at $0.11. Approximately 22,505 shares changed hands during trading, a decline of 56% from the average daily volume of 51,120 shares. The stock had previously closed at $0.08.
TC Biopharm（Holdings）Plc（納斯達克股票代碼：TCBPW — 獲取評級）股價在週一的交易中上漲了35.8％。該公司的交易價格高達0.12美元，最後一次交易價格爲0.11美元。交易期間約有22,505股易手，較平均每日交易量51,120股下降了56％。該股此前收於0.08美元。
TC Biopharm Stock Up 35.8 %
TC Biopharm股票上漲35.8％
The firm has a fifty day moving average price of $0.13 and a two-hundred day moving average price of $0.14.
該公司的五十天移動平均線價格爲0.13美元，兩百天移動平均線價格爲0.14美元。
Institutional Trading of TC Biopharm
TC Biopharm 的機構交易
A hedge fund recently bought a new stake in TC Biopharm stock. Nantahala Capital Management LLC acquired a new position in TC Biopharm (Holdings) Plc (NASDAQ:TCBPW – Get Rating) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 235,294 shares of the company's stock, valued at approximately $117,000.
一家對沖基金最近購買了TC Biopharm股票的新股份。根據Nantahala Capital Management LLC向美國證券交易委員會披露的最新信息，該公司在第一季度收購了TC Biopharm（Holdings）（納斯達克股票代碼：TCBPW — Get Ratinge）的新職位。該機構投資者收購了該公司235,294股股票，價值約11.7萬美元。
About TC Biopharm
關於 TC Bioparm
(Get Rating)
（獲取評分）
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its products pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; ImmuniStim, an unmodified cell therapy to treat COVID-19; TCB009 for the GI-tract cancer treatment; and TCB005/TCB006 that are allogeneic co-stimulatory GD-T CAR pre-clinical drug candidates would target antigens expressed on various solid tumor types.
TC Biopharm（Holdings）Plc是一家臨牀階段的生物製藥公司，專注於開發基於其異體伽瑪ΔT細胞平臺的免疫療法產品。其產品線包括OmnImmune，一種用於治療急性髓系白血病的未改性細胞療法；Immunistim，一種用於治療 COVID-19 的未改性細胞療法；用於治療胃腸道癌的 TCB009；以及同種異體共刺激 GD-T CAR 臨牀前候選藥物將靶向在各種實體瘤類型上表達的抗原 TCB005/TCB006。
Featured Stories
精選故事
- Get a free copy of the StockNews.com research report on TC Biopharm (TCBPW)
- This Is Why Penny Stock GreenPower Motor Company Is A Win
- Comcast Sum of All Parts is Producing a Cumulative Effect
- The Greenbrier Companies: All Aboard For High-Yield In 2023
- Coty Stock is on the Comeback Trail
- Splunk Stock is an AI-Powered Enterprise SEIM Play
- 免費獲取 StockNews.com 關於 TC Biopharm (TCBPW) 的研究報告
- 這就是爲甚麼 Penny stock GreenPower 汽車公司是贏家的原因
- Comcast 所有部件的總和正在產生累積效應
- Greenbrier 公司：在 2023 年全力爭取高收益
- Coty Stock 正在捲土重來
- Splunk Stock 是一款由人工智能驅動的企業 SEIM Play
Receive News & Ratings for TC Biopharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TC Biopharm and related companies with MarketBeat.com's FREE daily email newsletter.
接收 TC Biopharm 每日的新聞和評級 -在下面輸入您的電子郵件地址，即可通過Marketbeat.com的免費每日電子郵件時事通訊接收TC Biopharm及相關公司的最新新聞和分析師評級的簡明每日摘要。